Clinical Observation Of Rou Gan Hua Xian Pill In The Treatment Of Non-alcoholic Fatty Liver Fibrosis Of Liver Stagnation And Spleen Deficiency And Blood Stasis Type

Research Purpose In this study,rogan Huaxian pill,an anti-fibrosis/cirrhosis drug of our hospital,was selected to analyze its treatment of non-alcoholic fatty liver fibrosis of liver stagnation and spleen deficiency and blood stasis type.Methods A total of 62 outpatients who visited the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine and Jiujiang Traditional Chinese Medicine Hospital from October 2020 to September 2021 were selected and randomly divided into observation group and control group by random number table method,with 31 patients in each group.The observation group was treated with Roogan Huaxian pill,and the control group was treated with Silibinin capsules.Alanine aminotransferase(ALT)and asparagine aminotransferase(AST)γ-glutamyl transpeptidase(γ-GT)were detected.The level of laminin(LN)of type III procollagen(PCIII)and type IV collagen(IV-C)was detected by radioimmunoassay.The controlled attenuation parameter(CAP)and liver hardness value(LSM)were determined by instantaneous elastic wave scanner.Hepatic fibrosis 4 score(FIB-4)aspartate aminotransferase(ASpartate aminotransferase platelet ratio index)(APRI)BARD[BMI,AST/ALT,DM] score and BAAT[BMI,age,ALT,TG] score were used to evaluate liver fibrosis and observe before treatment Changes of above indexes in the two groups after 12 weeks of treatment.Results 1.Comparison of TCM symptom scores between the two groups before and after treatment There was no statistically significant difference in syndrome scores between the two groups before treatment(P > 0.05),and the symptom scores of the two groups after treatment were lower than before treatment,with statistically significant difference(P < 0.05).After treatment,the symptom score of the observation group was lower than that of the control group,the difference was statistically significant(P < 0.05).2.Comparison of liver damage hematological indexes between the two groups before and after treatment Before treatment,there were no significant differences in TG,TC,HDL-C,LDL-C,ALT,AST and γ-GT between the two groups(P > 0.05).After treatment,TG,TC,LDL-C,ALT,AST and γ-GT in 2 groups were significantly lower than before,while HDL-C was significantly higher than before,the difference was statistically significant(P < 0.01).After treatment,TG,TC,LDL-C and γ-GT in the observation group were significantly lower than those in the control group,the differences were statistically significant(P < 0.05).3.Comparison of non-invasive indexes of liver fibrosis between the two groups before and after treatment.Before treatment,there were no significant differences in HA,PC III,IV-C,LN,CAP,LSM,FIB-4,APRI,BARD and BAAT between the two groups(P >0.05).After treatment,HA,PC III,IV-C and LN in the two groups were significantly lower than before,the difference was statistically significant(P < 0.01),CAP,LSM,FIB-4,APRI,BARD and BAAT were significantly lower than before,the difference was statistically significant(P < 0.05).After treatment,the levels of HA,PC III,IV-C and LN in the observation group were significantly lower than those before treatment,the differences were statistically significant(P <0.01).After treatment,LSM in the observation group was significantly lower than that in the control group,the difference was statistically significant(P < 0.05).There were no significant differences in CAP,FIB-4,APRI and BAAT between the observation group and the control group after treatment(P > 0.05).Conclusion Rou Gan Hua Xian Pill has the function of protecting liver,improving liver function and resisting fibrosis.